Clinical application of Voriconazole treatment in invasive fungal infection for malignant hematology patients: a meta analysis
10.3969/j.issn.1006-5725.2015.14.041
- VernacularTitle:伏立康唑治疗恶性血液病并真菌感染临床应用Meta分析
- Author:
Leilei JIAN
;
Linhua JI
;
Zhanquan LI
;
Sen CUI
;
Juan SU
;
Wei LUO
- Publication Type:Journal Article
- Keywords:
Voriconazole;
Malignant hematology patients;
Invasive fungal infection;
Meta analysis;
Systemic evaluation
- From:
The Journal of Practical Medicine
2015;31(14):2368-2371
- CountryChina
- Language:Chinese
-
Abstract:
Objective To estimate the efficacy and safety of Voriconazole as antifungal prophylaxis of invasive fungal infection ( IFI) for malignant hematology patients. Methods The randomized controlled trials of Voriconazole treatment in invasive fungal infection for malignant hematology patients (ended in September 2014) were searched from Cochrane library, Medline, Embase, Pubmed, CBM, CNKI, Blood database. The meta analysis were performed by RevMan5.0. Results Ten literatures reported in 1 773 cases, in which there was significantly difference in effective rate between Voriconazole and other antifungal agents such as Amphotericin-B, Itraconazole, Micafungin and Fluconazole(P < 0.000 01); Four literatures indicated that there was significantly difference in adverse event rate between Voriconazole and amphotericin-B (P < 0.00 001); no significantly difference in adverse event rate between Voriconazole and amphotericin-B(P = 0.57); no significantly difference in adverse event rate between Voriconazole and Micafungin (P = 0.69); no significantly difference in adverse event rate between Voriconazole and Fluconazole (P = 0.70); Subgroup analysis indicated that adverse event rate between Voriconazole and Itraconazole is P=0.001, P = 0.17 respectively. Conclusion Voriconazole showed relative high efficient and low toxicity characteristics in treatment of malignant hematology accompanied by invasive fungal infection. But with its widely clinical application, the clinical value of Voriconazole needs to be further tested.
